false 0001614067 0001614067 2024-01-12 2024-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

January 12, 2024

 

 

 

Aridis Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38630   47-2641188
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I. R. S. Employer
Identification No.)

 

983 University Avenue, Bldg. B

Los Gatos, California 95032

(Address of principal executive offices, including ZIP code)

 

(408) 385-1742

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:
Common Stock   ARDS   OTC QB

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders

 

On January 12, 2024, Aridis Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 15,313,250 shares of common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on November 3, 2023 are as follows:

 

Proposal 1. Susan Windham-Bannister, Ph.D. was elected as a Class II director to serve until the 2026 Annual Meeting of Stockholders or until her successor has been duly elected and qualified, or until her earlier resignation, removal or death. The result of the vote to elect Susan Windham-Bannister was as follows:

 

Directors   For   Against   Abstain   Broker Non Vote  
Susan Windham-Bannister   13,643,878   0   396,561   1,272,811  

 

Proposal 2. The appointment of Grassi & Co., CPAs, P.C. as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2023 was ratified and approved by the stockholders by the votes set forth in the table below:

 

For   Against   Abstain   Broker Non Vote
14,978,646   167,331   167,273   0

 

Proposal 3. The non-binding advisory vote to approve the compensation of our principal executive officer, principal financial officer and each of our three other most highly compensated executive officers as of December 31, 2022 (collectively, the “Named Executive Officers”) was approved by the stockholders by the votes set forth in the table below:

 

For   Against   Abstain   Broker Non Vote
11,359,540   1,361,875   1,319,023   1,272,812

 

Proposal 4. The 2023 Omnibus Equity Incentive Plan was approved by the stockholders by the votes set forth in the table below:

 

For   Against   Abstain   Broker Non Vote
11,530,834   1,369,001   1,140,604   1,272,811

 

-2-
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: January 16, 2024 ARIDIS PHARMACEUTICALS, INC.
   
  /s/ Vu Truong
  Vu Truong
  Chief Executive Officer

 

-3-

v3.23.4
Cover
Jan. 12, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 12, 2024
Entity File Number 001-38630
Entity Registrant Name Aridis Pharmaceuticals, Inc.
Entity Central Index Key 0001614067
Entity Tax Identification Number 47-2641188
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 983 University Avenue
Entity Address, Address Line Two Bldg. B
Entity Address, City or Town Los Gatos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95032
City Area Code (408)
Local Phone Number 385-1742
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ARDS
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Aridis Pharmaceuticals (NASDAQ:ARDS)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Aridis Pharmaceuticals Charts.
Aridis Pharmaceuticals (NASDAQ:ARDS)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Aridis Pharmaceuticals Charts.